

**CURRICULUM VITAE
WAYNE G. RISKIN M.D., FACP, FACR**

EDUCATION:

University of Miami	1971
Rheumatology Fellowship	1979
Florida License Registration	1972

WORK HISTORY:

1979-present	Kahn and Riskin MD, PA
1986	Clinical Associate Professor, University of Miami

PROFESSIONAL ASSOCIATIONS:

1975	Diplomate, American Board of Internal Medicine
1975	Member, American College of Physicians
1975	Member, American College of Emergency Physicians
1982	Diplomate, Sub-Specialty Board of Rheumatology
1982-1986	Secretary/Treasurer, Florida Society of Rheumatology
1986-1988	Program Chairman, Florida Society of Rheumatology
1987-present	Member, Medical and Scientific Committee, Florida Chapter Arthritis Foundation
1989-1991	President, Florida Society of Rheumatology
1986-present	Fellow, American College of Rheumatology
1994	Fellow, American College of Physicians

MEMBERSHIPS IN MEDICAL ASSOCIATIONS:

Member, Broward County Medical Association
Member, Florida Medical Association
Member, American Medical Association

HOSPITAL AFFILIATIONS:

MEMORIAL REGIONAL HOSPITAL, HOLLYWOOD FL

1992-present	Chairman, Institutional Review Board
1992-present	Member, Library & Education Committee
1990-1992	Member, Institutional Review Board
1990-1992	Chairman, Credentials' Committee
1988-1990	Member, Credentials' Committee
1984-1988	Member, Utilization Committee

HOLLYWOOD MEDICAL CENTER, HOLLYWOOD, FL
MEMORIAL HOSPITAL WEST, HOLLYWOOD, FL
MEMORIAL PEMBROKE PINES, PEMBROKE PINES, FL

LICENSURE:

1971- Diplomat, National Board of Medical Examinations
1972- Florida
1972- California
1973- South Dakota

MEDICAL SCHOOL TEACHING AFFILIATIONS:

1981-1988 Clinical Assistant Professor
University of Miami School of Medicine
Department of Medicine
1986-2000 Voluntary Associate Professor
University of Miami School of Medicine
Department of Medicine
2000-present Volunteer Professor
University of Miami School of Medicine
Department of Medicine

RESEARCH STUDIES:

Effectiveness of Tolectin in the treatment of rheumatoid arthritis, McNell, 1973.

Effectiveness of Pirprofen in the treatment of rheumatoid arthritis, Ciba-Geigy, 1974.

Fenbufen in comparison with Placebo in patients with classical and definite rheumatoid arthritis, Lederie, 1977-1980.

Effectiveness of Oxaprozin in the treatment of degenerative joint disease, Wyeth 1979.

Levamisole rheumatoid arthritis study, Janssen R&D, Inc., 1979.

Isoxicam/buffered Aspirin double-blind study in the treatment of patients with active rheumatoid arthritis. Warner Lambert, 1980-1983.

Auranofin/Placebo with NSAID double-blind study in the treatment of patients with active rheumatoid arthritis. SKF, 1980-1982.

Double-blind study, comparing efficacy and safety of Tiflamizole (EN 350) with Placebo in osteoarthritis. Endo Laboratories, (Subsidiary of E.I. Du Pont de Nemours & Co., Inc.), 1982-1983.

Four-week, double-blind, randomized parallel long-term comparison of Naproxen 375 m.g., b.i.d. with Naproxen 750 m.g., b.i.d. in patients with rheumatoid arthritis. Syntex Laboratories, 1982-1983.

Double-blind, multi-center, controlled study of the efficacy and tolerability of Clinoril 300 mg. twice a day versus Clinoril 200 mgs. twice a day in the treatment of rheumatoid arthritis. Merck Sharp & Dohme Research Laboratories, 1983.

Open multicentric evaluation of the safety and efficacy of Tiflamizole (EN 350) in the long-term treatment of patients with osteoarthritis of the hip or knee. Endo Laboratories, Inc, (subsidiary of E.I. Du Pont de Nemours & Co., Inc.), 1983-1985.

Six-week, double-blind, controlled, randomized, parallel study to compare the efficacy and safety of 1000 MG Nabumetone to Placebo in the treatment of degenerative joint disease (Osteoarthritis). Beecham Laboratories, 1984-1985.

Twelve-month, open-label controlled evaluation of Nabumetone in the treatment of active osteoarthritis in adult patients. Beecham Laboratories, 1984-1988.

A Phase II, double-blind, multi-center study comparing the safety and efficacy of two dosing regimens of Tiflamizole in patients with rheumatoid arthritis. E.I. Du Pont de Nemours & Co., Inc., 1984-1985.

Wayne Riskin, MD, FACP, FACR

RESEARCH STUDIES:

Page 2

Comparative efficacy and safety of Disalcid and aspirin in rheumatoid arthritis patients. Riker Laboratories Inc., 1985-1986.

Open-label study of marketed NSAID treatment in patients with osteoarthritis using the Arthritis Impact Measurement Scales. Ciba Geigy, 1986-1988.

Open-label study of Voltaren treatment in patients with Osteoarthritis, Ciba Geigy, 1986-1988.

Phase III, double-blind study comparing the safety and efficacy of two doses of Azapropazone with Indomethacin in the treatment of acute gout. E.I. Du Pont de Nemours & Co., Inc., 1986.

Phase III, multi-center, double-blind study comparing the safety and efficacy of Azapropazone with Allopurinol in the management of chronic gout. E.I. Du Pont de Nemours & Co., Inc., 1986.

Multi-site, double-blind, parallel group comparison of Therafectin and Placebo as adjunctive therapy in patients with rheumatoid arthritis. Greenwich Pharmaceutical, 1986-1987.

Efficacy and safety study of daily oral administration of Tilomisolet in patients with active rheumatoid arthritis. Wyeth Laboratories, 1986.

Long-term open label safety and efficacy study for patients completing "A multi-site, double-blind, parallel group comparison of Therafectin and Placebo as adjunctive therapy in patients with rheumatoid arthritis." Greenwich Pharmaceutical, Inc., 1987-1988.

Open-label study of Voltaren treatment in patients with rheumatoid arthritis, Ciba Geigy, 1987-1988.

Open-label study of marketed NSAID treatment in patients with rheumatoid arthritis. Ciba Geigy, 1987-1988.

Double-blind, randomized study of Therafectin (Amiprilose HCL) 6 grams/day, compared to Placebo in patients with rheumatoid arthritis withdrawn from their non-steroidal anti-inflammatory drug therapy (RA9 and RA10). Greenwich, Pharmaceutical, Inc. 1987-1988.

Wayne Riskin, MD, FACP, FACR

RESEARCH STUDIES:

Page 3

Sonotron Device Study--Osteoarthritis of the knee. ADM Tronics, 1988.

Open-label extension study of Therafectin (Amiprilose HCL) 6 grams/day in patients completing RA9.

Open-label extension study of Therafectin (Amiprilose HCL) 6 grams/day in patients completing RA10.

Six-week, multiple-dose safety and efficacy comparison of Naproxen multi-particulate C 1000 MG tablets to Naproxen standard tablets in patients with arthritis followed by Open-label treatment with multi-particulate C tablets alone. Syntex Laboratories, 1989.

Randomized, double-blind withdrawal of Therafectin (Amiprilose HCL), followed by a 52 week open-label extension study in rheumatoid arthritic patients. (RA11). Greenwich Pharmaceutical, Inc. 1989.

Four-week Placebo controlled comparison of the efficacy and safety of orally administered Etodolac and Diclofenac in patients with degenerative joint disease of the knee, followed by a 12-week, double-blind comparison of Etodolac and Diclofenac. Wyeth Ayerst Research, 1989-1990.

Comparison of the efficacy and safety of orally administered Etodolac and Piroxicam in patients with active rheumatoid arthritis. Wyeth Ayerst Research, 1989-1990.

Efficacy, safety, and tolerability evaluation of Diclofenac sodium vs. Naproxen in the treatment of rheumatoid arthritis. Ciba Geigy, 1989-1990.

Nine-month, double-blind, Placebo controlled multiple dose efficacy and safety study of RS 61443-000 in patients with rheumatoid arthritis. Syntex Research, 1990.

Four-week single-blind efficacy and safety study of Feldene versus Voltaren in the treatment of patients with rheumatoid arthritis. Pfizer Laboratories, 1990.

A 104 week open-label use study of background anti-rheumatic therapy and rescue medication in patients treated with Therafectin (RA 11W). Greenwich Pharmaceutical, Inc. 1990.

One-year, open-label, multiple dose efficacy and safety extension study of RS 61443-000 in patients with rheumatoid arthritis. Syntex research. 1991-1992.

Wayne Riskin, MD, FACP, FACR

RESEARCH STUDIES:

Page 4

Double-blind comparison of Nabumetone and Indomethacin in the treatment of moderate to severe osteoarthritis patients as outpatients. SmithKline Beecham, 1992.

Fifty-six week, double blind comparison of the safety and efficacy of Bromfenac and Ibuprofen in patients with active osteoarthritis of the hip or knee with Placebo control during the first four weeks. Wyeth/Ayerst Research, 1992.

A multicenter, randomized, double-blind, placebo-controlled parallel group study to determine the efficacy and safety of Risedronate in the treatment of Osteoporosis in elderly woman. Proctor and Gamble, 1994-Present

Searle--Double-Blind, Placebo-Controlled, Randomized Comparison Study of the Efficacy and Safety of Two Doses of SC-58635 BID and Naproxen 500 mg. BID in Treating the Signs and Symptoms of Rheumatoid Arthritis 1996-present.

Searle--Clinical Protocol to Evaluate the Long-Term Safety of SC-58635 in Treating the Signs and Symptoms of Osteoarthritis and Rheumatoid Arthritis 1996-present.

Roche--A Double-Blind, Randomized, Parallel Group, Multicentre Comparison of the Efficacy and Safety of Mycophenolate Mofetil (MMF-RS61443) PO (1 g BID) and Placebo in Patients with Active Rheumatoid Arthritis (6-Month Efficacy Study) Who are Candidates for Immunosuppressive Therapy of RA 1997-present.

Millennium Pharmaceuticals, Inc.--Rheumatoid arthritis genetic Epidemiology study, 1997.

HYAL Pharmaceutical Corporation--A multicentre, double-blind, placebo-controlled, parallel group clinical study to evaluate the efficacy and safety of topical 3% Diclofenac gel (HYANALGESE-D) in the treatment of pain associated with osteoarthritis of the knee. 1997-present.

Double-blind, randomized, placebo-controlled study of Therafectin (Amiprilose HCL) in rheumatoid arthritis patients concomitantly treated and then withdrawn from non-steroidal anti-inflammatory drug therapy (RA 12), Greenwich Pharmaceutical, 1992.

Wayne Riskin, MD, FACP, FACR

RESEARCH STUDIES:

Page 5

Nine-month, double-blind, multiple dose efficacy and safety comparison of Mycophenolate Mofetil, 2 gms. daily versus 4 gms. daily in rheumatoid arthritis patients. Syntex research 1992.

Searle--A Multi-center, Double Blind, Parallel Group Study comparing the Incidence of Clinically Significant Upper Gastrointestinal Adverse Events Associated with SC-58635 400 mgs. BID to that of Ibuprofen in Patients with Osteoarthritis or Rheumatoid Arthritis 1999-present.

Roche--A Double-blind, randomized parallel group, multi-center comparison of the efficacy and safety of Mycophenolate Mofetil (MMF-RS61443) PO (1g bid) and placebo in patients with active rheumatoid arthritis (6-month efficacy study) who are candidates for immunosuppressive therapy of RA.

An open-label, multi-center study administering Mycophenolate Mofetil (MMF-RS 61443) po (1 g bid) in patients with active rheumatoid arthritis (extension of protocol BA15428). 1998-1999.

Roche--A Double-blind, randomized, stratified, parallel-group study to assess the incidence of PUBs during chronic treatment with MK-0966 or Naproxen in patients with rheumatoid arthritis (purple study).

Merck--A Randomized, Placebo Controlled, Parallel Group, Double Blind Study to Evaluate the Efficacy And Safety of MK-066 12.5 mg., visualized. Nabumetone 1000 mgs., in patients with osteoarthritis of the knees; protocol 090-00.

BIBLIOGRAPHY:

- Stay, LE, Riskin, WG: Algorithm Directed Triage in an Emergency Department. *J. Amer. Coll. Emerg., Phys.*, 5 (11) 869-875-, 1976.
- Riskin, WG, Topek, K: Pulmonary Dirofilaria: Another Coin Lesion. *S. Med. J.* 70:502-502, 1977.
- Gottlieb, NL, Riskin, WG: Arthropathy Associated with Cutaneous Polyarteritis *Arth. Rheum*, 21:2, 281-282 (letter), March 1978.
- Riskin, WG, Altman, R. Latta, L. Tennenbaum, J: Osteoarthritis in Canine Articular Cartilage. *Transactions of the American Academy of Orthopedic Research* (Abstract). February 1978.
- Gottlieb, NL, Riskin, WG: Complications of Local Corticosteroid Injections. *JAMA*, 243:15, 1547-1548, April 1980.
- Gottlieb, NL, Riskin, WG: et al: A Clinical Metabolic Study of Auranofin in Rheumatoid Arthritis. *Clin. Res.*, 28: 1980.
- Gottlieb, NL, Riskin, WG: Methylprednisolone Pulse Therapy in Rheumatoid Arthritis. *Clin. Res.*, 28: 1980.
- Gottlieb, NL, Riskin, WG et al: Extended Experience with Auranofin in Rheumatoid Arthritis. *Proc. 44th Ann. Meet. Amer. Rheum. Assoc. in Arth. And Rheum.* 23:6; 654. June 1980.
- Kahn, CB, Riskin, WG: Routine Laboratory Monitoring with Non-steroidal Anti-Inflammatory Drugs (Letter to the Editor). *J. Fla Med. Assn.*, Vol. 70 (10), October 1983.
- Altman, RD, Riskin, WG: Biomechanical and Biochemical Properties of Dog Cartilage in Experimentally Induced Osteoarthritis. *Ann. Rheum.*, 43:83-90 1984.
- Kolodny, AL, Klipper, AR, Harris, BK, Howard, FM, Kahn, CB, Riskin, WG, Weaver, AL, Wilkens, R: Efficacy and Safety of Single Daily Doses of Oxaprozin in the Treatment of Osteoarthritis: A Comparison with Aspirin. *Seminars in Arthritis and Rheumatism*. Vol. XV (3), Suppl. 2, February 1986.
- Riskin, WG, Gillings, DB, Scarlett, JA: Amiprilose Hydrochloride for Rheumatoid Arthritis. *Ann. Int. Med.* Vol. III (6) September 15, 1989.